Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity

v3.19.1
Stockholders' Equity
6 Months Ended
Jan. 31, 2019
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]

Note 9 – Stockholders’ Equity


Controlled Equity Offering


The Company has a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”). Under the Sales Agreement, the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”). The Company pays Cantor a commission of 3.0% of the aggregate gross proceeds received under the Sale Agreement. The Company is not obligated to make any sales of the shares under the Sales Agreement. The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. The initial agreement contemplated the sale of shares of the Company’s common stock having an aggregate offering price of up to $20.0 million. In December 2014, the Sales Agreement was amended in order for the Company to offer and sell additional shares of Common Stock having an aggregate offering price of $20.0 million.


On September 1, 2017, the Company filed with the SEC a “shelf” registration and sales agreement prospectus covering the offering, issuance and sale of our Common Stock that may be issued and sold under the existing Sales Agreement in an aggregate amount of up to $19.15 million. A total of $150 million of securities may be sold under this shelf registration, which was declared effective September 15, 2017.


During the six months ended January 31, 2019 and 2018, the Company did not sell any shares of Common Stock under the Sales Agreement.


Share-based compensation


On January 14, 2011, the Company’s stockholders approved the adoption of the 2011 Incentive Plan (the “2011 Plan”) which provides for the issuance of equity awards, including among others, options, restricted stock and restricted stock units for up to 3,000,000 Common Shares. The exercise price of options granted under the 2011 Plan, and consistent with other Plans, is equal to or greater than fair market value of the Common Stock on the date of grant. Unless terminated earlier by the Board of Directors, the 2011 Plan will terminate at the earliest of; (a) such time as no shares of Common Stock remain available for issuance under the 2011 Plan or (b) tenth anniversary of the effective date of the 2011 Plan. On January 5, 2018, the Company’s stockholders approved the amendment and restatement of the 2011 Plan to increase the number of shares available for issuance by 2,000,000 bringing the total number of shares available for award under the 2011 Plan to 5,000,000. Awards outstanding upon expiration of the 2011 Plan shall remain in effect until they have been exercised, terminated, or have expired.


The amounts of share-based compensation expense recognized in the periods presented are as follows:


    Three months ended
January 31,
    Six months ended
January 31,
 
    2019     2018     2019     2018  
Stock options   $ 289     $ 205     $ 521     $ 407  
Restricted stock     2       3       5       6  
    $ 291     $ 208     $ 526     $ 413  

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:


    Three months ended
January 31,
    Six months ended
January 31,
 
    2019     2018     2019     2018  
Selling, general and administrative   $ 291     $ 208     $ 526     $ 413  
    $ 291     $ 208     $ 526     $ 413  

No excess tax benefits were recognized during the six month periods ended January 31, 2019 and 2018.


Stock Option Plans


The following table summarizes stock option activity during the six month period ended January 31, 2019:


    Options     Weighted
Average
Exercise
Price
    Weighted
Average
Remaining
Contractual
Term
    Aggregate
Intrinsic
Value (000s)
 
Outstanding at July 31, 2018     1,882,116     $ 4.96                  
Awarded     725,821     $ 2.81                  
Exercised     (238,230 )   $ 2.69             $ 117  
Cancelled or expired     (2,000 )   $ 4.51                  
Outstanding at end of period     2,367,707     $ 4.53       3.4 years     $ 811  
Exercisable at end of period     1,148,101     $ 5.23       1.1 years     $ 112  

As of January 31, 2019, the total future compensation cost related to non-vested options, not yet recognized in the statements of operations, was $1.4 million and the weighted average period over which the remaining expense of these awards is expected to be recognized is eighteen months.


The intrinsic value of in the money stock option awards at the end of the period represents the Company’s closing stock price on the last trading day of the period in excess of the exercise price multiplied by the number of options.


During the three months ended January 31, 2019 certain directors and officers of the Company exercised 203,511 stock options in non-cash transactions. The officers and directors received 23,376 net shares of common stock. The Company did not receive any proceeds from this exercise. The net shares issued represent the difference between the fair market value of the options on the date of exercise less the strike price cost to exercise the options.


Performance Stock Units


To better align the long-term interest of executives with growing U.S. practices, beginning in fiscal 2018, the Company granted long-term incentive awards in the form of time based stock options and performance-based restricted stock units (“Performance Stock Units” or “PSUs”). The PSUs earned will be determined over a three-year performance period. The primary performance metrics will be revenue and Adjusted EBITDA growth. Payouts based on revenue and adjusted EBITDA goals will be modified based on Total Shareholder Return (“TSR”) performance relative to Enzo’s peer group.


During fiscal year 2018 and 2019, the Company awarded PSUs to its executive officers, this award provides for the grant of shares of our common stock at the end of a three–year period based on the achievement of average revenue growth and adjusted EBITDA growth over that period. As of January 31, 2019, the Company did not accrue any compensation expense for these PSU’s as the three-year performance period has just begun and achievement of the growth goals is currently not probable.


  Period
Ending
    Total
Grant
    Fair Market Value
Grant Date (000s)
    7/31/2018       32,000     $ 141  
    1/31/2019       81,500     $ 229  

Restricted Stock Awards


The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of January 31, 2019, there were 1,626 shares of unvested restricted stock which have a weighted average award price of $1.74 per share. As of January 31, 2019, there was approximately $11 of unrecognized compensation cost related to these unvested shares of restricted stock to be recognized over a weighted average remaining period of approximately twenty-four months. There were no awards made during the six months ended January 31, 2019. During the six months ended January 31, 2019, 985 restricted stock awards vested whose fair value was approximately $4.


The total number of shares available for grant as equity awards from the 2011 Incentive Plan is approximately 1,208,000 shares as of January 31, 2019.